Impact of nanoscience and nanotechnology on controlled drug delivery

Nanomedicine

Volumn 3, Issue 4, 2008, Pages 401-406

  Youan, Bi Botti Celestin ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; BIOMATERIAL; CYTOTOXIC AGENT; DRUG CARRIER; LIPID; LIPOSOME; NANOPARTICLE; PEPTIDE DERIVATIVE; PLASMID DNA; POLYARGININE; POLYCAPROLACTONE; POLYGLACTIN; POLYLEUCINE; POLYMER; UNCLASSIFIED DRUG;

BACTERIOPHAGE; CANCER CELL; CANCER RESISTANCE; CELL HOMING; CELL MIGRATION; CELL VACUOLE; CHEMICAL ANALYSIS; COLLOID; COMBINATORIAL CHEMISTRY; COMPUTER AIDED DESIGN; CONFIDENTIALITY; CONTROLLED DRUG RELEASE; DIAGNOSTIC TEST; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; EDITORIAL; ELECTRON BEAM; EMULSION; FOOD AND DRUG ADMINISTRATION; GENE DELIVERY SYSTEM; HEMATOPOIETIC STEM CELL; HIGH THROUGHPUT SCREENING; HUMAN; MEDICAL ETHICS; MOLECULAR ELECTRONICS; NANOENCAPSULATION; NANOMEDICINE; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; PATIENT MONITORING; PHARMACEUTICAL CARE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY CONTROL; RESEARCH SUBJECT; RISK BENEFIT ANALYSIS; SYNTHESIS; TARGET CELL;

DRUG DELIVERY SYSTEMS; NANOMEDICINE; NANOTECHNOLOGY;

EID: 56549101146     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.3.4.401     Document Type: Editorial

References (49)

1. Hallberg D, Schuberth O, Wretlind A: Experimental and clinical studies with fat emulsion for intravenous nutrition. Nutr. Dieta. Eur. Rev. Nutr. Diet 8, 245-281 (1966).
2. Howard RE, Liao PF, Skocpol WJ, Jackel LD, Craighead HG: Microfabrication as a scientific tool. Science 221, 117-121 (1983).
3. Binnig G, Frank KH, Fuchs H et al.: Tunneling spectroscopy and inverse photoemission: image and field states. Phys. Rev. Lett. 55, 991-994 (1985).
4. Amato I: Candid cameras for the nanoworld. Science 276, 1982-1985 (1997).
5. Feynman R: There is plenty of room at the bottom. In: Miniaturization. Gilbert HD (Ed.). Reinhold, NY, USA 282-296 (1961).
6. Moghimi SM, Hunter AC, Murray JC: Nanomedicine: current status and future prospects. FASEB J. 19, 311-330 (2005).
7. Allen TM, Cullis PR: Drug delivery systems: entering the mainstream. Science 303, 1818-1822 (2004).
8. Batrakova EV, Kabanov AV: Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release (2008) (Epub ahead of print).
9. Torchilin VP: Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24, 1-16 (2007).
10. Discher BM, Won YY, Ege DS et al.: Polymersomes: tough vesicles made from diblock copolymers. Science 284, 1143-1146 (1999).
11. Devalapally H, Chakilam A, Amiji MM: Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci. 96, 2547-2565 (2007).
12. Moghimi SM, Hunter AC, Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001).
13. Pearce ME, Melanko JB, Salem AK: Multifunctional nanorods for biomedical applications. Pharm. Res. 24, 2335-2352 (2007).
14. Kogure K, Akita H, Yamada Y, Harashima H: Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. Adv. Drug Deliv. Rev. 60, 559-571 (2008).
15. Ye Z, Mahato RI: Role of nanomedicines in cell-based therapeutics. Nanomed. 3, 5-8 (2008).
16. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R: Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751-760 (2007).
17. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
18. Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750-763 (2002).
19. Couvreur P, Vauthier C: Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23, 1417-1450 (2006).
20. Forrest ML, Kwon GS: Clinical developments in drug delivery nanotechnology. Adv Drug Deliv. Rev. 60, 861-862 (2008).
21. Sumer B, Gao J: Theranostic nanomedicine for cancer. Nanomed. 3, 137-140 (2008).
22. Nel A, Xia T, Madler L, Li N: Toxic potential of materials at the nanolevel. Science 311, 622-627 (2006).
23. Chan VS: Nanomedicine: an unresolved regulatory issue. Regul. Toxicol. Pharmacol. 46, 218-224 (2006).
24. Bawa R, Johnson S: The ethical dimensions of nanomedicine. Med. Clin. North Am. 91, 881-887 (2007).
25. Hughes T, Andrews B, Boone C: Old drugs, new tricks: using genetically sensitized yeast to reveal drug targets. Cell 116, 5-7 (2004).
26. Mack JT, Brown CB, Tew KD: ABCA2 as a therapeutic target in cancer and nervous system disorders. Expert Opin. Ther. Targets 12, 491-504 (2008).
27. Pasqualini R, Ruoslahti E: Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366 (1996).
28. Schmidmaier R, Baumann P: Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr. Med. Chem. 15, 978-990 (2008).
29. Laird DJ, von Andrian UH, Wagers AJ: Stem cell trafficking in tissue development, growth, and disease. Cell 132, 612-630 (2008).
30. Oh P, Borgstrom F, Witkiewicz H et al.: Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat. Biotechnol. 25, 327-337 (2007).
31. Cheong I, Huang X, Thornton K, Diaz LA, Zhou S: Targeting cancer with bugs and liposomes: ready, aim, fire. Cancer Res. 67, 9605-9608 (2007).
32. Juliano R: Bugging tumors to put drugs on target. N. Engl. J. Med. 356, 954-955 (2007).
33. Maywood ES, O'Neill J, Wong GK, Reddy AB, Hastings MH: Circadian timing in health and disease. Prog. Brain Res. 153, 253-269 (2006).
34. Youan BB: Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J. Control. Release 98, 337-353 (2004).
35. Rabinow BE: Nanosuspensions in drug delivery. Nat. Rev. Drug Discov. 3, 785-796 (2004).
36. Tu RS, Tirrell M: Bottom-up design of biomimetic assemblies. Adv. Drug Deliv. Rev. 56, 1537-1563 (2004).
37. Geng Y, Dalhaimer D, Cai S et al.: Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2, 249-255 (2007).
38. Farokhzad OC, Karp JM, Langer R: Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv. 3, 311-324 (2006).
39. Holowka EP, Sun VZ, Kamei DT, Deming TJ: Polyarginine segments in block copolypeptides drive both vesicular assembly and intracellular delivery. Nat. Mater. 6, 52-57 (2007).
40. Green JJ, Langer R, Anderson DG: A combinatorial polymer library approach yields insight into nonviral gene delivery. Acc. Chem. Res. (2008) (Epub ahead of print).
41. Gratton SE, Pohlhaus PD, Lee J, Guo J, Cho MJ, Desimone JM: Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. J. Control. Release 121, 10-18 (2007).
42. LaVan DA, Lynn DM, Langer R: Moving smaller in drug discovery and delivery. Nat. Rev. Drug Discov. 1, 77-84 (2002).
43. Lengyel JS, Milne JL, Subramaniam S: Electron tomography in nanoparticle imaging and analysis. Nanomed. 3, 125-131 (2008).
44. Li F, Zhou X, Zhu J, Ma J, Huang X, Wong ST: High content image analysis for human H4 neuroglioma cells exposed to CuO nanoparticles. BMC Biotechnol. 7, 66 (2007).
45. Zapata P, Su J, Garcia AJ, Meredith JC: Quantitative high-throughput screening of osteoblast attachment, spreading, and proliferation on demixed polymer blend micropatterns. Biomacromolecules 8, 1907-1917 (2007).
46. Lionberger RA: FDA critical path initiatives: opportunities for generic drug development. AAPS J. 16, 103-109 (2008).
47. Balzani V, Credi A: Artificial molecular-level machines. Chem. Rec. 1, 422-435 (2001).
48. Drexler KE: Molecular engineering: an approach to the development of general capabilities for molecular manipulation. Proc. Natl Acad. Sci. USA 78, 5275-5278 (1981).
49. Benenson Y, Gil B, Ben-Dor U, Adar R, Shapiro E: An autonomous molecular computer for logical control of gene expression. Nature 429, 423-429 (2004).